MENLO PARK, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated CORT today announced it will report its third quarter 2018 financial results and provide a corporate update on November 1, 2018. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
To participate, dial 1-877-260-1479 from the United States or 1-334-323-0522 internationally approximately 10 minutes before the start of the call. The passcode is 7489528.
A replay will be available through November 15, 2018 at 1-888-203-1112 from the United States and 1-719-457-0820 internationally. The passcode will be 7489528.
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym® is the company's first FDA-approved medication. Corcept has a large portfolio of proprietary compounds that selectively modulate the effects of cortisol but not progesterone. Corcept owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators, including Korlym, to treat a wide variety of serious disorders.
CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
crobb@corcept.com
www.corcept.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
